Taipei Exchange - Delayed Quote TWD

OBI Pharma, Inc. (4174.TWO)

Compare
56.90
+0.70
+(1.25%)
At close: 1:30:31 PM GMT+8
Currency in TWD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
69,549.00
41,549.00
4,711.00
18,772.00
140,886.00
Cost of Revenue
138,925.00
115,046.00
44,855.00
44,362.00
6,469.00
Gross Profit
-69,376.00
-73,497.00
-40,144.00
-25,590.00
134,417.00
Operating Expense
2,067,163.00
2,016,294.00
2,082,618.00
1,690,424.00
1,600,298.00
Operating Income
-2,136,539.00
-2,089,791.00
-2,122,762.00
-1,716,014.00
-1,465,881.00
Net Non Operating Interest Income Expense
41,615.00
85,020.00
45,941.00
2,660.00
39,234.00
Pretax Income
-2,294,818.00
-1,275,554.00
-1,917,092.00
-1,742,253.00
-1,493,691.00
Tax Provision
-10,874.00
-9,594.00
-17,768.00
-24,363.00
-3,794.00
Net Income Common Stockholders
-2,106,566.00
-1,046,475.00
-1,613,916.00
-1,530,687.00
-1,377,935.00
Diluted NI Available to Com Stockholders
-2,106,566.00
-1,046,475.00
-1,613,916.00
-1,530,687.00
-1,377,935.00
Basic EPS
-9.14
-4.54
-7.23
-7.64
-7.22
Diluted EPS
-9.14
-4.54
-7.23
-7.65
-7.22
Basic Average Shares
230,643.85
230,411.48
223,447.33
200,123.51
201,792.32
Diluted Average Shares
230,643.85
230,411.48
223,447.33
200,123.51
201,792.32
Total Expenses
2,206,088.00
2,131,340.00
2,127,473.00
1,734,786.00
1,606,767.00
Net Income from Continuing & Discontinued Operation
-2,106,566.00
-1,046,475.00
-1,613,916.00
-1,530,687.00
-1,377,935.00
Normalized Income
-2,106,566.00
-1,046,475.00
-1,613,916.00
-1,530,687.00
-1,377,935.00
Interest Income
52,127.00
92,957.00
49,931.00
6,458.00
43,418.00
Interest Expense
10,512.00
7,937.00
3,990.00
3,798.00
4,184.00
Net Interest Income
41,615.00
85,020.00
45,941.00
2,660.00
39,234.00
EBIT
-2,284,306.00
-1,267,617.00
-1,913,102.00
-1,738,455.00
-1,489,507.00
EBITDA
-2,064,938.00
-1,018,664.00
-1,666,492.00
-1,522,180.00
-1,257,668.00
Reconciled Cost of Revenue
138,925.00
115,046.00
44,855.00
44,362.00
6,469.00
Reconciled Depreciation
219,368.00
248,953.00
246,610.00
216,275.00
231,839.00
Net Income from Continuing Operation Net Minority Interest
-2,106,566.00
-1,046,475.00
-1,613,916.00
-1,530,687.00
-1,377,935.00
Normalized EBITDA
-2,064,938.00
-1,018,664.00
-1,666,492.00
-1,522,180.00
-1,257,668.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 12/12/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

4147.TWO TaiMed Biologics Inc.
86.50
+0.35%
 
4162.TWO PharmaEngine, Inc.
95.10
+2.15%
 
3176.TWO Medigen Biotechnology Corp.
32.60
-1.21%
 
4743.TWO Oneness Biotech Co., Ltd.
79.70
+1.66%
 
6589.TWO EirGenix Inc.
79.80
+1.01%
 
6541.TW Tanvex BioPharma, Inc.
65.30
+3.98%
 
6550.TW Polaris Group
43.40
+0.46%
 
6535.TWO Lumosa Therapeutics Co., Ltd.
263.50
-0.57%
 
6492.TWO Senhwa Biosciences, Inc.
42.35
+0.47%
 
4130.TWO Genovate Biotechnology Co., Ltd.
25.30
+1.81%